LZLei Zhang

Lei Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lei Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tu-Si-Zi-Wan reduces D-galactose-induced hepatic and cerebral oxidative damage in aging mice via the Nrf2/ARE pathway

    by Guoping He, Di Wu, Juanjuan Wang, Lei Zhang, Chunyan Zhang, Xiaozhi Liu, Xiangli Han

    The global aging population necessitates safe, multi-target strategies to combat age-related functional decline. Tu-Si-Zi-Wan (TSZW), a classical medicinal-dietary formula documented in ancient Chinese medical texts and composed of Cuscuta chinensis and Dioscorea opposita, demonstrates multitargeted potential, yet its systemic antiaging mechanisms remain unclear. This study investigated the protective effects of TSZW on hepatic and neurological aging through the Nrf2/ARE pathway while exploring its systemic impact on metabolic and immune homeostasis. Firstly, network pharmacology predicted the targets and pathways of TSZW, identifying 113 shared TSZW-aging targets, with Nrf2, IL-6, and HIF-1α as core nodes enriched in oxidative stress-related pathways. Secondly, a D-galactose-induced aging mouse model was established, followed by 4 months of TSZW intervention (low, medium, and high doses). Behavioral tests (open field, novel object recognition, and grip strength), metabolic and inflammatory marker detection, histopathology, and molecular analyses (western blot, quantitative PCR, and immunofluorescence) were used to assess systemic aging phenotypes, oxidative damage, and Nrf2/ARE pathway activity. TSZW dose-dependently improved motor activity, cognition, and muscle strength; restored liver/kidney function (ALT, AST, Cr, and urea); reduced the serum levels of tumor necrosis factor-α, interleukin 6, and interleukin-1β; and attenuated hepatic/neuronal damage. It suppressed the expression of senescence markers (p16, p21, and p53) while increasing the expression of antioxidant enzymes (SOD and GSH-Px) and reducing oxidative damage (MDA and ROS). Mechanistically, TSZW promoted Nrf2 nuclear translocation; upregulated Hmox1, Nqo1, and Gclm expression; and inhibited Keap1. Notably, high-dose TSZW outperformed vitamin E in reversing immune organ atrophy (thymus and spleen indices) and preserving hippocampal neurons. Collectively, TSZW alleviates hepatic and neurological aging via Nrf2/ARE-mediated antioxidant signaling, with concurrent mitigation of systemic aging phenotypes, including immune organ atrophy and chronic inflammation. Its multicomponent synergy highlights Traditional Chinese medicinal cuisine's potential for systemic anti-aging intervention by targeting oxidative stress-inflammation-metabolic signaling crosstalk.

  • Open Access

    Xifeng Jiannao pill mitigates MPTP-induced neuronal apoptosis by reducing inflammation and oxidative stress via MAPK signaling

    by Xiangli Han, Guoping He, Juanjuan Wang, Hanxi Lou, Lei Chen, Lei Zhang, Boyang Liu, Di Wu, Xiaozhi Liu, Su Wang, et al.

    Xifeng Jiannao Pill (XFJNP), a traditional Chinese medicine formulation, has been shown to alleviate clinical symptoms in patients with Parkinson’s disease (PD). However, the underlying mechanisms remain unclear. Therefore, this study employs network pharmacology and molecular biology to investigate the potential therapeutic mechanisms of XFJNP. Firstly, network pharmacology is utilized to screen the major active ingredients and potential targets of XFJNP in the treatment of PD. Following this, pathway enrichment analysis is conducted to gain insights into the underlying mechanisms. Secondly, an MPP+-induced SH-SY5Y cell model and an MPTP-induced PD mouse model to investigate the therapeutic effects and potential mechanisms of XFJNP on PD. By assessing apoptosis, oxidative stress (OS), inflammation, activation of the MAPK pathway, and conducting behavioral tests in mice, we aimed to elucidate the efficacy and underlying mechanisms of XFJNP in treating PD. Network pharmacology analysis indicates that the MAPK signaling pathway holds a key position in mediating the therapeutic effects of XFJNP for PD. In basic experimental studies, XFJNP significantly enhanced the survival rate of MPP+-induced SH-SY5Y cells in vitro, reduced OS and inflammation levels, and increased the expression of tyrosine hydroxylase (TH) protein. In the MPTP-induced PD mouse model, XFJNP effectively improved motor function and reduced the loss of dopaminergic (DA) neurons. Mechanistic studies suggest that XFJNP may mitigate OS and inflammatory responses in the substantia nigra by inhibiting the excessive activation of ERK, JNK, and p38 in the MAPK signaling pathway. Based on the results of network pharmacology analysis and experimental validation, XFJNP displays profound neuroprotective efficacy by modulating the MAPK signaling cascade, markedly diminishing neuroinflammation and mitigating OS-triggered apoptosis of DA neurons in PD models. Graphical Abstract